Forendo Pharma is a clinical stage drug development company, with core competencies in tissue specific hormone mechanisms and therapeutic focus in women’s health. The company was founded in 2013 by leading academic endocrinology experts and Finnish drug development pioneers. Forendo is supported by strong international investors: Novo Seeds, Karolinska Development, Novartis Venture Fund, Vesalius Biocapital III Partners, M Ventures and Innovestor. The company’s pipeline includes HSD17B1 inhibitor (phase I) for the treatment of endometriosis; dual HSD inhibitors (discovery) for the treatment of broader gynecological conditions; and Fispemifene (phase 2), a novel SERM for the treatment of male urological conditions. Further information is available at www.forendo.com.